Optimization of a carbon monoxide (CO) sensing hemoprotein for applications as an antidote for CO poisoning and a biosensor for CO detection in living cells
优化一氧化碳 (CO) 传感血红蛋白作为 CO 中毒解毒剂的应用和用于活细胞中 CO 检测的生物传感器
基本信息
- 批准号:10643257
- 负责人:
- 金额:$ 16.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-06-10 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AcuteAddressAffinityAmino AcidsAntidotesBindingBiologicalBiosensorCRISPR/Cas technologyCalibrationCarbon MonoxideCarbon Monoxide PoisoningCardiacCellsCessation of lifeChemicalsClinicalClinical ResearchCytoprotectionDetectionDevelopmentDiagnosisDiseaseEmergency department visitErythrocytesExhibitsFluorescenceFunctional disorderHealthHemeHemeproteinsHemoglobinHumanIn VitroInfectionInflammationInhalationInorganic ChemistryIntravenousIntravenous infusion proceduresIschemiaKineticsLearningLigandsMammalian CellMentorshipMetabolismMethodsModelingMolecularMolecular TargetMorbidity - disease rateMusNeurocognitiveNeurocognitive DeficitOrganOrganismOutcomeOxygenPatient-Focused OutcomesPatientsPatternPersonsPhysiologicalPoisoningProductionProliferatingPropertyRecombinantsReperfusion InjuryReporterReporter GenesResearch PersonnelRoleSafetySignal PathwaySignal TransductionSignaling MoleculeSpectrophotometrySurvivorsTestingTherapeuticTherapeutic AgentsTissuesToxic effectToxicologyTransfectionTransgenic OrganismsUnited StatesVariantbiophysical chemistrycareercell growthchemical stabilitycircadian regulationconventional therapydesigndetectordisabilityexperiencehemodynamicsimprovedin vivoinduced pluripotent stem cell derived cardiomyocytesinnovationinsightlong-term sequelaemicrobialmortalitymouse genomemouse modelorgan injuryorgan transplant rejectionpoint of carepre-clinicalpreclinical studypressurepreventresponsesafety assessmentscaffoldsensorskillsstandard of caretooltranscription factor
项目摘要
PROJECT SUMMARY/ABSTRACT
Carbon monoxide (CO) inhalation is a leading cause of human poisoning in the United States, resulting in about
50,000 cases and at least 1,500 deaths annually, as well as long-term cardiac and neurocognitive sequelae for
one-third of survivors. Unfortunately, no point of care antidotal therapy exists for CO poisoning to date. A field-
deployable agent that irreversibly scavenges and sequesters CO could serve as an improved therapeutic that
increases survival and long-term outcomes for patients suffering from CO poisoning. In this proposal, we will
exploit the uniquely strong and specific interaction between CO and ferrous heme by utilizing a hemoprotein
scaffold to develop a high-affinity CO scavenger. We recently discovered a remarkable hemoprotein domain,
found in the bacterial CO-sensing transcription factor RcoM (regulator of CO metabolism), that exhibits a 900-
fold increase in CO binding affinity compared to hemoglobin, the primary biological target in acute CO poisoning.
This RcoM hemoprotein also shows exquisite selectivity for CO over oxygen, a critical property for a CO antidote
that will be infused intravenously in humans under oxygenated conditions. In Aim 1, we will utilize in vitro
spectroscopic methods to identify 1) the minimum functional RcoM subunit, and 2) key amino acid residues that
confer high CO affinity, selectivity, and heme stability. In Aim 2, we will evaluate the safety and efficacy of the
three RcoM truncates with highest CO affinity and selectivity in vivo. We will assess systemic and organ-specific
effects of intravenous RcoM delivery in healthy mice and quantify the ability of infused RcoM to scavenge CO,
reverse hemodynamic collapse, and prevent death in a severe preclinical mouse model of CO poisoning. The
outcomes of these aims will provide fundamental insight into hemoprotein ligand selectivity and demonstrate the
therapeutic potential of recombinant RcoM as a treatment for acute CO poisoning. While toxic at high
concentrations, CO, endogenously produced as a by-product of heme degradation, serves as a cytoprotective
signal at low concentrations. Preclinical and clinical studies have explored the use of CO as a therapeutic under
conditions ranging from infection to ischemia/reperfusion injury. Despite potential clinical benefits, the roles of
CO as a signaling molecule are poorly understood, and the CO concentration regimes corresponding to basal
signaling, cytoprotection, and toxicity are poorly defined. A genetically encoded, CO-selective fluorescent
reporter would be the ideal tool to tease apart physiological roles of CO in living systems. In Aim 3, we will
employ the CO-sensing function of RcoM to design a genetically encoded fluorescent reporter, characterize CO-
dependent response in vitro, and incorporate this reporter into the mouse genome using CRISPR/Cas9. We will
quantify CO accumulation in transgenic reporter mice under different CO exposure conditions and define regimes
that give rise to CO signaling, cytoprotection, and toxicity in vivo. Through this aim, we will develop critical
biomolecular tools that will enable elucidation of CO-dependent signaling mechanisms relevant to human health.
项目概要/摘要
一氧化碳 (CO) 吸入是美国人类中毒的主要原因,导致约
每年有 50,000 例病例和至少 1,500 人死亡,以及长期心脏和神经认知后遗症
三分之一的幸存者。不幸的是,迄今为止,还没有针对一氧化碳中毒的即时解毒疗法。一片田野——
不可逆地清除和隔离二氧化碳的可部署制剂可以作为一种改进的治疗方法
增加一氧化碳中毒患者的生存率和长期结果。在本提案中,我们将
利用血红素蛋白,利用 CO 和亚铁血红素之间独特的强而特异的相互作用
支架开发高亲和力的CO清除剂。我们最近发现了一个显着的血红素蛋白结构域,
第 900 章
与血红蛋白(急性一氧化碳中毒的主要生物靶标)相比,一氧化碳结合亲和力增加了数倍。
这种 RcoM 血红蛋白还表现出对 CO 相对于氧气的精细选择性,这是 CO 解毒剂的关键特性
将在含氧条件下静脉注射到人体中。在目标 1 中,我们将利用体外
光谱方法来鉴定 1) 最小功能 RcoM 亚基,以及 2) 关键氨基酸残基
赋予高 CO 亲和力、选择性和血红素稳定性。在目标 2 中,我们将评估该药物的安全性和有效性
三个 RcoM 截短物在体内具有最高的 CO 亲和力和选择性。我们将评估系统性和器官特异性
静脉注射 RcoM 对健康小鼠的影响并量化输注的 RcoM 清除 CO 的能力,
在严重的临床前一氧化碳中毒小鼠模型中逆转血流动力学崩溃并防止死亡。这
这些目标的结果将为血红蛋白配体选择性提供基本见解,并证明
重组 RcoM 作为治疗急性 CO 中毒的治疗潜力。虽然在高浓度下有毒
浓度,CO,作为血红素降解的副产品内源产生,作为细胞保护剂
低浓度下的信号。临床前和临床研究探索了使用 CO 作为治疗剂
从感染到缺血/再灌注损伤的各种情况。尽管有潜在的临床益处,但其作用
人们对 CO 作为信号分子知之甚少,并且与基础值相对应的 CO 浓度方案
信号传导、细胞保护和毒性的定义不明确。基因编码的共选择性荧光
记者将成为梳理二氧化碳在生命系统中生理作用的理想工具。在目标 3 中,我们将
利用 RcoM 的 CO 传感功能设计基因编码的荧光报告基因,表征 CO-
体外依赖性反应,并使用 CRISPR/Cas9 将该报告基因整合到小鼠基因组中。我们将
量化转基因报告小鼠在不同 CO 暴露条件下的 CO 积累并确定方案
产生 CO 信号传导、细胞保护和体内毒性。通过这一目标,我们将开发关键的
生物分子工具将能够阐明与人类健康相关的CO依赖性信号传导机制。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Nitric oxide and thiols: Chemical biology, signalling paradigms and vascular therapeutic potential.
一氧化氮和硫醇:化学生物学、信号范式和血管治疗潜力。
- DOI:
- 发表时间:2023-10-31
- 期刊:
- 影响因子:7.3
- 作者:Dent, Matthew R;DeMartino, Anthony W
- 通讯作者:DeMartino, Anthony W
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Matthew Ryan Dent其他文献
Matthew Ryan Dent的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Matthew Ryan Dent', 18)}}的其他基金
Development of a carbon monoxide scavenging hemoprotein as a novel antidotal therapy to treat inhaled CO poisoning
开发一氧化碳清除血红蛋白作为治疗吸入性一氧化碳中毒的新型解毒疗法
- 批准号:
10387161 - 财政年份:2022
- 资助金额:
$ 16.32万 - 项目类别:
相似国自然基金
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
相似海外基金
B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers
传染病、自身免疫和 B 细胞癌症背景下的 B 细胞生物学
- 批准号:
10683443 - 财政年份:2023
- 资助金额:
$ 16.32万 - 项目类别:
TNFRSF13B polymorphisms and immunity to transplantation
TNFRSF13B 多态性与移植免疫
- 批准号:
10734879 - 财政年份:2023
- 资助金额:
$ 16.32万 - 项目类别:
A novel bioengineering approach to restoring permanent periodontal inflammatory bone loss
一种恢复永久性牙周炎性骨质流失的新型生物工程方法
- 批准号:
10734465 - 财政年份:2023
- 资助金额:
$ 16.32万 - 项目类别:
Development of the waixenicin A pharmacophore as a therapeutic intervention for neonatal hypoxic brain injury
开发 Waixenicin A 药效团作为新生儿缺氧性脑损伤的治疗干预措施
- 批准号:
10577489 - 财政年份:2023
- 资助金额:
$ 16.32万 - 项目类别:
Smartphone-based POC Testing for HIV Using Glowstick Chemistry
基于智能手机的 HIV 使用荧光棒化学进行 POC 测试
- 批准号:
10594143 - 财政年份:2023
- 资助金额:
$ 16.32万 - 项目类别: